Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
@weezul what is ur target price? Thanks!
$8b in debt?
I pointed a recent example where azn has been issued crl on pdufa date
Recently all abuse deterrent opiod formulations had adcoms before the pdufa date. The adcom is convened atleast month ahead of pdufa date. As elite doesnt have an adcom scheduled and we are just few days away from pdufa, three things can happen, fda can request more information by issuing a crl(more likely), or fda can move the pdufa date citing it needs more time(less likely) or it can approve the product without an adcom (very unlikely).
Zsph/azn got crl for zs-9 on the pdufa date..
I have seen crl been given on the pdufa date. So watch out.
I would respectfully disagree. I think pdufa date will be delayed. This is given.
Are there any analysts covering eltp? What are the price targets. I have few shares and want to add more for the run up to pdufa but I see the mc to be at 250m. Thats lot. What do you guys think? Thanks.
SRNE acquires 6 million $nk shares. With the current price at 8$ it implies 48$ million in investment. With 52wk high of 38$, we may expect this investment reach 250$ million. Adds almost 7$ to the srne price.
Reverse merger with an indian company with operations in US. More info from the vc investor http://www.biomarkcapital.com/portfolio/#strand-life-sciences
What is the short %? Thanks.
Finally profitable in eltp. Cost averaging helped.. Target exit price 0.8$
I see that an analyst from morgan stanley was there in the cc. Is it the first time?
They are open label trials... So possible to have look ins into data as they come
I am tempted to buy more shared at this level. I feel good about it this time.
If aaic news is substantial and tv networks cover the new alz test, the nasdaq listing would really take off to new heights.
When are the next earnings report?
Hmm..if pphm says opdivo will be soc and will be reiumbursible then what happens to the Sunrise trial. doce is used as comparator arm in sunrise.. Can fda request one more trial with soc and that is the reason pphm is planning trials with opdivo?
How is this a good thing for pphm? He will be pushing his invention earger than bavi.
How do we know it is dilution and not short selling?
Hmm.. So all phase 2 trials.. So oncs is not far behind..
Wow.. What a search?! Now gliobastoma is considered to be related to merkel cell.. Never knew.. Thanks doctor.
Hold your horses till the abstracts are posted. Ambs submitted the late breaking abstracts once they are accepted pr will be issued.
Are they presenting any new data?
$acad. They had to delay the nda because the manufacturing was not in place.
what is meant was the sunrise trial is studying Bavi+Docetaxel vs Docetaxel alone while BMY checkmate trial is Opdivo vs Docetaxel. So, bavi needs Docetaxel to be effective.
True. I will take my loss and move on if the opdivo data is spectacular.
They were referring to opdivo being used for squamous cancer. However todays bmy opdivo halt is in the non-squamous cancer nonsmall cell lung cancer. Same target as the sunrise trial. The mos is not announced yet but it is really bothering if it bests bavi as seen in p2.
It would be really calming if the management can assign a number to the statement 'enrollment going on as planned'.
I am only interested in data from sunrise trial. I don't bother if AF or Brad approve of pphm.
Brad is pals with AdamF. I don't think he will say anything positive. I am sure.
New chief legal officer. The data must be good to defend against celgene
Data next week. Giddy up..
One good thing about PPHM when looking at ACAD debacle is that we have manufacturing capabilities and come NDA filing there wouldnt not be any delay.
I mean, they should have looked at what the competition is doing. If those companies have filed NDA recently, it would mean they have started P3 a while ago. Elite should have paid attention to it and not proceed on blind faith for the lack of money. If ART is the way going forward, they should made every effort to be at forefront, but not be a me too in that space.
Looks like lot of competition.
http://www.pharmacytimes.com/product-news/FDA-to-Review-2-Abuse-Deterrent-Opioids
And all the companies mentioned in the article submitted NDA based on P3. How did Elite miss that and not start with P3 much earlier?
I was reading through anti-cd47, it seems similar in action to anti-PS. It is still in early stages, celgene just started P1 on that.
Cynviloq enrollment complete:
http://sorrentotherapeutics.com/news/news-display/?id=122561
Expect to see the data by the end of march.